var data={"title":"Sodium polystyrene sulfonate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium polystyrene sulfonate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6971?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-polystyrene-sulfonate-drug-information\" class=\"drug drug_general\">see &quot;Sodium polystyrene sulfonate: Drug information&quot;</a> and <a href=\"topic.htm?path=sodium-polystyrene-sulfonate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium polystyrene sulfonate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50579343\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sodium Polystyrene Sulfonate (Kayexalate) Safety Alert</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA is recommending that patients avoid taking sodium polystyrene sulfonate (Kayexalate) concurrently with other oral medications after a study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medicines, decreasing their absorption and effectiveness. To reduce this likelihood, the dosing of sodium polystyrene sulfonate should be separated from other orally administered medicines by at least 3 hours, with that time increased to 6 hours for patients with gastroparesis or other conditions resulting in delayed gastric emptying. Sodium polystyrene sulfonate drug labeling will be updated to include information about this dosing separation. Patients should not stop taking their potassium-lowering medicines without first talking with their health care providers.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm574763.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=19eF/P9pFIY5u/Dk4IRlD+SO0IfB3xT0yWo9d7Su8dTi/AdYfEU3ebe1EzWHbNarQFNmYoHQcj4o8DeavyHFVFm5zPdJxovsrBuhldO8X8sgYAhiebX8k8pHjTfITTNm6uMNty2yanj5aninEiXbRNc/iaWVM63GCvbrG2VsWwwuqTGfQp8Rq78xsQsDuebT&amp;TOPIC_ID=12799\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm574763.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222030\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Kalexate [DSC];</li>\n      <li>Kayexalate;</li>\n      <li>Kionex;</li>\n      <li>SPS</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222031\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Kayexalate;</li>\n      <li>PMS-Sodium Polystyrene Sulfonate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062273\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hyperkalemia</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445048\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia, treatment (not first-line):</b> Limited data available: <b>Note:</b> Due to delayed onset of action, sodium polystyrene sulfonate should not be used an emergency treatment for life-threatening hyperkalemia. Generally, not recommended for use in premature neonates due to their GI hypomotility and subsequent risk of complications, including but not limited to NEC and hypernatremia; per manufacturer labeling, use is contraindicated in neonates with reduced gut motility.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm and term neonates: Rectal: 1 g/kg/dose with a 15 to 30 minute retention every 4 to 6 hours in combination with other ongoing therapies to reduce serum K; monitor serum potassium frequently and discontinue resin therapy promptly when able (Eichenwald 2017; Malone 1991; Yaseen 2008); may employ lower doses by using the exchange ratio of 1 mEq K<sup>+</sup>/g of sodium polystyrene sulfonate resin as the basis for calculation. <b>Note:</b> Sorbitol-free formulation is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pretreatment of infant formula or expressed breast milk; to decrease potassium load for renal failure patients:</b> Limited data available; various approaches reported: Term neonates: Usual dose: ~1 g/100 mL of infant formula or expressed breast milk, adjust dose based on patient serum potassium trends; reported dose range: 0.4 to 1.5 g/100 mL (Thompson 2013). When using infant formula, some experts recommend using 1g/mEq K<sup>+ </sup>content of the formula (Taylor 2015). After addition of resin to formula/breast milk, shake vigorously to mix, allow to sit under refrigeration for 60 minutes, then decant liquid for infant feed and leave precipitate at the bottom. In addition to decreasing the potassium load of the feed (subsequently patient's serum K) (Taylor 2015; Thompson 2013), other electrolyte concentrations may also be decreased (eg, Ca, Mg, Cu, Zn) in the formulas and increases in sodium concentrations of the feed; patients should be monitored closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062267\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sodium-polystyrene-sulfonate-drug-information\" class=\"drug drug_general\">see &quot;Sodium polystyrene sulfonate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperkalemia: </b>Limited data available: <b>Note: </b>Typically not first-line; used when necessary to increase potassium excretion (Lehnhardt 2011). Due to delayed onset of action, sodium polystyrene sulfonate should not be used an emergency treatment for life-threatening hyperkalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Weight-based dosing</i>: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, nasogastric: 1 g/kg/dose every 6 hours; maximum dose: 15 g/dose; <b>Note:</b> Oral route more effective than rectal and is preferred (Fuhrman 2017; Lehnhardt 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rectal: 1 g/kg/dose every 2 to 6 hours; maximum dose range: 30 to 50 g/dose; retain at least 15 to 60 minutes (Fuhrman 2017; Lehnhardt 2011); <b>Note:</b> Sorbitol-free preparations are preferred (Fuhrman 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Exchange-ratio based dosing</i>: Infants and small children: Oral, nasogastric, rectal: 1 mEq K<sup>+</sup>/g of sodium polystyrene sulfonate resin as the basis for calculation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pretreatment of formula or expressed breast milk; decrease potassium load for renal failure patients:</b> Limited data available; various approaches reported: Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Infant/Enteral formula</i>: 0.5 to 2.6 g/100 mL of formula (Cameron 2013; Thompson 2015) <b>or</b> 0.25 to 1g/mEq K<sup>+ </sup>content of formula (Fassinger 1998; Taylor 2015), adjust dose based on patient serum potassium trends. After addition of the resin, shake vigorously to mix, allow to sit under refrigeration for 30 to 60 minutes, then decant liquid for feed and leave precipitate at the bottom. The extent of potassium removal depends on the formula; in one trial, Similac PM 60/40 samples showed significant decreases at additive amounts of 0.25 to 1 g/mEq K<sup>+</sup> content of formula versus Suplena which only showed significant reduction of K<sup>+</sup> concentrations in the formula at 1 g/mEq K<sup>+</sup> content of formula (Taylor 2015). Other electrolyte concentrations may also be decreased (eg, Ca, Mg, Cu, Zn) and significant increases in sodium concentrations of the formula were consistently reported; patients should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Expressed breast milk:</i> Usual dose: ~1 g/100 mL; adjust based on patient serum potassium trends; reported dose range: 0.4 to 1.5 g/100 mL of expressed breast milk. After addition of the resin, shake vigorously to mix, allow to sit under refrigeration for 60 minutes, then decant liquid for infant feed and leave precipitate at the bottom. In addition to decreasing the potassium load of the feed (subsequently patient's serum K) (Thompson 2013), other electrolyte concentrations may also be decreased (eg, Ca, Mg, Cu, Zn) and sodium concentrations (breast milk and serum) increased; patients should be monitored closely (Thompson 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 15 g 1 to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: 30 to 50 g every 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222010\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kalexate: (454 g [DSC]) [sorbitol free; contains sodium 100 mg (4.1 mEq)/g]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kayexalate: (453.6 g) [contains sodium 100 mg (4.1 mEq)/g]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kionex: (454 g) [contains sodium 100 mg (4.1 mEq)/g]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: (15 g, 453.6 g, 454 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kionex: 15 g/60 mL (60 mL, 473 mL) [contains alcohol, usp, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium 1500 mg (65 mEq)/60 mL, sorbitol; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SPS: 15 g/60 mL (60 mL, 120 mL, 473 mL) [contains alcohol, usp, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium 1500 mg (65 mEq)/60 mL, sorbitol; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 15 g/60 mL (60 mL, 480 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 30 g/120 mL (120 mL); 50 g/200 mL (200 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221996\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062276\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral or NG: Administer orally or via NG tube with patient in an upright position at least 3 hours before or 3 hours after other medications (patients with gastroparesis may require a 6 hour separation). Do not mix in orange juice or any fruit juice known to contain potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Shake commercially available suspension well before use.<b></b>Chilling the oral mixture will increase palatability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder for suspension: Powdered resin must be mixed with water or syrup prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Route is less effective than oral administration. Administer cleansing enema first. Each dose of the powder for suspension should be suspended in an aqueous vehicle and administered as a warm emulsion (body temperature). The commercially available suspension should also be warmed to body temperature. During administration, the solution should be agitated gently. Retain enema in colon: Neonates: 30 minutes; in older patients: At least 30 to 60 minutes and for several hours, if possible. Once retention time is complete, irrigate colon with a nonsodium-containing solution to remove resin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222027\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store repackaged product in refrigerator and use within 14 days. Freshly prepared suspensions should be used within 24 hours. Do not heat resin suspension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062275\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of hyperkalemia (FDA approved in pediatric patients [age not specified] and adults); has also been used as pretreatment of infant formulas/expressed breast milk to lower the potassium load for renal failure patients (acute and chronic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222054\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kayexalate may be confused with Kaopectate</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sodium polystyrene sulfonate may be confused with calcium polystyrene sulfonate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Always prescribe either one-time doses or as a specific number of doses (eg, 15 g q6h x 2 doses). Scheduled doses with no dosage limit could be given for days leading to dangerous hypokalemia.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kionex [US] may be confused with Kinex brand name for biperiden [Mexico]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222052\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypernatremia, hypocalcemia, hypokalemia, hypomagnesemia, sodium retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, diarrhea, fecal impaction, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Bezoar formation, gastrointestinal hemorrhage, gastrointestinal ulcer, intestinal necrosis, intestinal perforation, ischemic colitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222018\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sodium polystyrene sulfonate, polystyrene sulfonate resins or any component of the formulation; hypokalemia (excluding Kayexalate); obstructive bowel disease; neonates with reduced gut motility; oral administration in neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications: Suspension: Rectal administration in neonates (particularly in premature infants).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222000\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspiration: Acute bronchitis and bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported; patients with impaired gag reflex, altered level of consciousness or patients prone to regurgitation may be at increased risk. Administer with the patient in an upright position.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte disturbances: Severe hypokalemia may occur; frequent monitoring of serum potassium is recommended within each 24-hour period; ECG monitoring may be appropriate in select patients. Cation-exchange resins may also affect other cation concentrations, possibly resulting in decreased serum magnesium and calcium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fecal impaction: Large oral doses may cause fecal impaction (especially in elderly); rectal administration has been associated with fecal impaction in children.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intestinal necrosis: Intestinal necrosis (including fatalities) and other serious gastrointestinal events (eg, bleeding, ischemic colitis, perforation) have been reported, especially when administered with sorbitol; concomitant administration of sorbitol is not recommended. Increased risk may be associated with a history of intestinal disease or surgery, hypovolemia, prematurity, and renal insufficiency or failure. Use only in patients who have normal bowel function. Avoid use in any postoperative patient at risk for constipation or impaction until normal bowel function resumes; discontinue use if constipation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe heart failure and/or hypertension; sodium load may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edema: Use with caution in patients with edema; sodium load may exacerbate condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Higher doses in elderly patients may result in fecal impaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Oral administration in neonates and use in neonates with reduced gut motility (postoperatively or drug-induced) is contraindicated. Oral or rectal administration of suspension in neonates (particularly with prematurity) is also contraindicated. Use with caution in premature or low-birth-weight infants. Use with caution in children when administering rectally; excessive dosage or inadequate dilution may result in fecal impaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Effective lowering of serum potassium from sodium polystyrene sulfonate may take hours to days after administration; consider alternative measures (eg, dialysis) or concomitant therapy (eg, IV sodium bicarbonate) in situations where rapid correction of severe hyperkalemia is required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Enema vs oral administration: Enema will reduce the serum potassium faster than oral administration, but the oral route will result in a greater reduction over several hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535382\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300068\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222004\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12799&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Sodium Polystyrene Sulfonate may enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction.  Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin. Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Sodium Polystyrene Sulfonate may enhance the adverse/toxic effect of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Laxatives (Magnesium Containing): May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Sodium Polystyrene Sulfonate may decrease the serum concentration of Lithium.  Management: Consider separating administration of lithium from administration of oral sodium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meloxicam: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sorbitol: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Sodium Polystyrene Sulfonate may decrease the serum concentration of Thyroid Products.  Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13851578\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Some liquids may contain potassium: Management: Do not mix in orange juice or in any fruit juice known to contain potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222006\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11510210\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration. Use during pregnancy is not expected to result in significant exposure to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062272\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum sodium, potassium, calcium, magnesium, ECG, and acid/base status (if applicable)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221999\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Removes potassium by exchanging sodium ions for potassium ions in the intestine (especially the large intestine) before the resin is passed from the body; the practical exchange capacity is 1 mEq potassium per 1 g of resin in vivo, and in vitro capacity is 3.1 mEq of potassium per 1 g of resin, therefore, a wide range of exchange capacity exists such that close monitoring of serum electrolytes is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222017\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hours to days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Completely feces (primarily as potassium polystyrene sulfonate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062281\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">1 g of resin binds &sim;1 mEq of potassium; 4.1 mEq sodium per g of powder; 1 level teaspoon contains 3.5 g polystyrene sulfonate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222021\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Kionex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 g/60 mL (60 mL): $11.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Sodium Polystyrene Sulfonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 g/60 mL (473 mL): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Sodium Polystyrene Sulfonate Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 g/120 mL (120 mL): $44.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (SPS Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 g/60 mL (120 mL): $56.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222023\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kayexalate (BB, BE, BM, BS, BZ, FR, GY, IL, IT, JM, LU, SR, TH, TT, VN);</li>\n      <li>Kexelate (ZA);</li>\n      <li>Kuzem (TW);</li>\n      <li>Resinsodio (ES, MY, SG);</li>\n      <li>Resonium (DK, FI, PT, SE);</li>\n      <li>Resonium A (AT, AU, GB, HK, HN, MY, NL, PL, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cameron JC, Kennedy D, Feber J, Wong E, Geier P, Vaillancourt R. Pretreatment of infant formula with sodium polystyrene sulfonate: focus on optimal amount and contact time. <i>Paediatr Drugs</i>. 2013;15(1):43-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/23329388/pubmed\" target=\"_blank\" id=\"23329388\">23329388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fassinger N, Dabbagh S, Mukhopadhyay S, Lee DY. Mineral content of infant formula after treatment with sodium polystyrene sulfonate or calcium polystyrene sulfonate. <i>Adv Perit Dial</i>. 1998;14:274-277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/10649740/pubmed\" target=\"_blank\" id=\"10649740\">10649740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Philadelphia, PA: Elsevier Health; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/21181208/pubmed\" target=\"_blank\" id=\"21181208\">21181208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone TA, &quot;Glucose and Insulin Versus Cation-Exchange Resin for the Treatment of Hyperkalemia in Very Low Birth Weight Infants,&quot; <i>J Pediatr</i>, 1991, 118(1):121-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/1986079/pubmed\" target=\"_blank\" id=\"1986079\">1986079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rivard AL, Raup SM, Beilman GJ. Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(2):76-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/15080600/pubmed\" target=\"_blank\" id=\"15080600\">15080600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor JM, Oladitan L, Carlson S, Hamilton-Reeves JM. Renal formulas pretreated with medications alters the nutrient profile. <i>Pediatr Nephrol</i>. 2015;30(10):1815-1823.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/25930981/pubmed\" target=\"_blank\" id=\"25930981\">25930981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson K, Flynn J, Okamura D, Zhou L. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(&reg;)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency. <i>J Ren Nutr</i>. 2013;23(5):333-339.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/23707305/pubmed\" target=\"_blank\" id=\"23707305\">23707305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vemgal P and Ohlsson A, &quot;Interventions for Non-Oliguric Hyperkalaemia in Preterm Neonates,&quot; <i>Cochrane Database Syst Rev</i>, 2007, (1):CD005257.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/17253550/pubmed\" target=\"_blank\" id=\"17253550\">17253550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yaseen H, Khalaf M, Dana A, et al, &quot;Salbutamol Versus Cation-Exchange Resin (Kayexalate) for the Treatment of Nonoliguric Hyperkalemia in Preterm Infants,&quot; <i>Am J Perinatol</i>, 2008, 25(3):193-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/18425722/pubmed\" target=\"_blank\" id=\"18425722\">18425722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12799 Version 77.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50579343\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F222030\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F222031\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062273\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445048\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062267\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222010\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F221996\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062276\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F222027\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062275\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F222054\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222052\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222018\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222000\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535382\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300068\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222004\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13851578\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222006\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11510210\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062272\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221999\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F222017\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1062281\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F222021\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F222023\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12799|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-polystyrene-sulfonate-drug-information\" class=\"drug drug_general\">Sodium polystyrene sulfonate: Drug information</a></li><li><a href=\"topic.htm?path=sodium-polystyrene-sulfonate-patient-drug-information\" class=\"drug drug_patient\">Sodium polystyrene sulfonate: Patient drug information</a></li></ul></div></div>","javascript":null}